Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase
Graphical abstract
Section snippets
Acknowledgments
This work was partially supported by the Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation and Indiana Genomics Initiative (INGEN) of Indiana University, which is supported in part by Lilly Endowment Inc. The authors thank Dr. Bruce H. Mock, Barbara E. Glick-Wilson, and Michael L. Sullivan for their assistance in production of 11CH3OTf. The referees’ criticisms and editor’s comments for the revision of the manuscript are greatly appreciated.
References and notes (13)
- et al.
Nucl. Med. Biol.
(1999) - et al.
J. Labelled Compd. Radiopharm.
(2003) - et al.
Mol. Cancer Ther.
(2005) - et al.
Xenobiotica
(2004) - et al.
Xenobiotica
(2004) - et al.
J. Nucl. Med.
(1997)
Cited by (110)
Metal-Tyrosine Kinase Inhibitors: Targeted metal-drug conjugates
2022, Coordination Chemistry ReviewsIndustrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles-catalyzed hydrogenation of nitroarenes
2022, Catalysis CommunicationsFDA approved six-membered ring fused pyrimidine-based derivatives
2022, Fused Pyrimidine-Based Drug DiscoveryManufacturable Process of a Novel EGFR Inhibitor (Larotinib) for the Treatment of ESCC
2022, Organic Process Research and DevelopmentFDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application
2021, European Journal of Medicinal ChemistryCitation Excerpt :To date, several synthetic routes have been reported previously [51–54]. Among them, one representative route is depicted in Scheme 1 [51]. 3-Hydroxy-4-methoxybenzaldehyde (GEFT-001) reacts with formate/formic acid and hydroxylamine sulfate, giving 3-hydroxy-4-methoxybenzonitrile (GEFT-002).
pH-sensitive biomaterials for cancer therapy and diagnosis
2020, Biomaterials for Cancer Therapeutics: Evolution and Innovation